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Abstract
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Antibodies (inhibitors) developed by hemophilia B patients against coagulation factor IX (FIX)
are challenging to eliminate because of anaphylaxis or nephrotic syndrome after continued
infusion. To address this urgent unmet medical need, FIX fused with a transmucosal carrier (CTB)
was produced in a commercial lettuce (Simpson Elite) cultivar using species specific chloroplast
vectors regulated by endogenous psbA sequences. CTB-FIX (~1mg/g) in lyophilized cells was
stable with proper folding, disulfide bonds and pentamer assembly when stored ~2 years at
ambient temperature. Feeding lettuce cells to hemophilia B mice delivered CTB-FIX efficiently to
the gut immune system, induced LAP+ regulatory T cells and suppressed inhibitor/IgE formation
and anaphylaxis against FIX. Lyophilized cells enabled 10-fold dose escalation studies and
successful induction of oral tolerance was observed in all tested doses. Induction of tolerance in
such a broad dose range should enable oral delivery to patients of different age groups and diverse
genetic background. Using Fraunhofer cGMP hydroponic system, ~870 kg fresh or 43.5 kg dry

*

Author Manuscript

Correspondence: Prof. Henry Daniell, Director of Translational Research, University of Pennsylvania, 240 South 40th Street, 547
Levy Building, Philadelphia PA 19104-6030, Phone: 215-746-2563, hdaniell@upenn.edu. Prof. Roland W. Herzog, University of
Florida, Cancer and Genetics Research Center, 2033 Mowry Road, CGRC, Room 203, Gainesville, FL 32610, Phone: 352-273-8113,
FAX: 352-273-8342, rherzog@ufl.edu.
1Jin Su and Liqing Zhu contributed equally to this study.
2current address: First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Author contributions
HD and RWH conceived and supervised the study and designed experiments. JS, RWH and HD wrote the manuscript. JS contributed
data to figures 1–3; Data and related text for figure 4 was contributed by JS, SL, AK, JHN and SJS; LZ, AS, XW contributed data in
figures 5, 6. All authors participated in data analysis.

Competing financial interests
Henry Daniell is an inventor in several US and international patents on chloroplast transformation technology to produce
biopharmaceuticals, in particular induction of oral tolerance. Henry Daniell and Roland Herzog are co-inventors in hemophilia
patents. Novo Nordisk is currently funding the hemophilia project.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Su et al.

Page 2

Author Manuscript

weight can be harvested per 1000 ft2 per annum yielding 24,000–36,000 doses for 20-kg pediatric
patients, enabling first commercial development of an oral drug, addressing prohibitively
expensive purification, cold storage/transportation and short shelf life of current protein drugs.
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1. Introduction
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Biopharmaceuticals produced in current systems are prohibitively expensive and are not
affordable for large majority of the global population. The cost of protein drugs ($140
billion in 2013) exceeds GDP of >75% of countries around the globe, making them
unaffordable in these countries [1]. One third of global population earning <$2 per day can’t
afford any protein drug. Although recombinant insulin is sold commercially for five
decades, it is still not affordable for a large majority of global population. This is because of
their production in prohibitively expensive fermenters, purification, cold storage/
transportation, short shelf life and sterile delivery methods.
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Production of biopharmaceutical proteins in plants provides a cost-effective solution. Oral
delivery of protein drugs bioencapsulated in plant cells significantly reduces downstream
processing costs by eliminating expensive purification, cold storage/transportation, and short
shelf life [2–4]. Plant cells expressing therapeutic proteins can be inexpensively processed
by lyophilization and stored at room temperature for several months or years without
impacting their therapeutic efficacy [4,5]. Plants can also be grown in the field with
appropriate biological containment of foreign genes, such as maternal inheritance or male
sterility and/or harvest of vegetative tissues before flowering [6].
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Oral delivery of protein drugs has been elusive for decades because of their degradation in
the digestive system, inability to cross the gut epithelium and delivery to target cells.
However, several recent studies have unequivocally shown that plant cell wall protects
expressed protein drugs from acids and enzymes in the stomach via bio-encapsulation [2–4].
Human digestive enzymes are incapable of breaking down glycosidic bonds in
carbohydrates that make up plant cell wall. However, when intact plant cells containing
protein drugs reach the gut, commensal microbes digest plant cell wall and release protein
drugs in the gut lumen. Bacteria inhabiting the human gut have evolved to utilize complex
carbohydrates in plant cell wall and are capable of utilizing almost all plant glycans [7,8].
Fusion of the (nontoxic) Cholera toxin B subunit (CTB) to a reporter protein (GFP)
expressed in chloroplasts and bioencapsulated in plant cells was orally delivered across the
gut epithelium through GM1 receptors and furin cleavage site engineered between CTBGFP released GFP into circulation or different tissues [9]. Fusion of CTB to therapeutic
proteins facilitate their effective oral delivery for induction of oral tolerance [10–13] or
deliver functional proteins to sera [5,14,15] or across blood brain or retinal barriers [15,16].
Hemophilia is an X-linked bleeding disorder caused by mutations in coagulation factor VIII
(FVIII, hemophilia A) or factor IX (FIX, hemophilia B). Hemophilia patients are currently
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treated by replacement therapy with recombinant or plasma-derived factor concentrate.
However, 20–30% of patients with severe hemophilia A (as defined by <1% coagulation
activity) and ~5% of severe hemophilia B patients develop inhibitory antibodies (or
“inhibitors”), which seriously complicate treatment and increase morbidity and mortality of
the disease [17–19]. Therefore, immune tolerance induction to eliminate these inhibitors is
required to restore effectiveness of factor replacement therapy. Current clinical protocols for
reversal of the antibody response via immune tolerance induction (ITI) require frequent
high-dose factor administration for prolonged periods (from months to more than 1 year),
and the costs are extremely high (often exceeding one million dollars) [18]. Among
hemophilia B patients, those with F9 gene deletions are at an elevated risk for inhibitor
formation. Often ITI protocols for FIX inhibitors cannot be completed because of
anaphylactic reactions or development of nephrotic syndrome [20]. There are currently no
prophylactic ITI protocols to prevent inhibitor formation. Such a protocol should ideally
avoid immune suppressive drugs because inhibitors tend to form at a very young age (during
the first 50 days of exposure) [18]. To address this unmet medical need, we are developing
an oral tolerance protocol using clotting factors expressed in plant cells [11–13,21].
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In this study, we created FIX-transplastomic plants in an edible system ideal for oral
delivery. Production of protein drugs in chloroplasts offers several unique advantages
including high-level expression (up to 70% total leaf protein) [22], transgene containment
from pollen transmission via maternal inheritance of transgenes and lack of gene silencing/
position effect due to site specific integration of the transgenes [23]. Although we
suppressed inhibitor formation and anaphylaxis against human FIX in hemophilia B mice
using tobacco cells [11, 13] further clinical development was not feasible. We report here
the first successful development and large scale production of CTB-FIX in a cGMP facility
in an edible crop plant (lettuce) and evaluation of therapeutic efficacy in a wide dose range
and product stability.

2. Materials and methods
2.1. Construction of lettuce chloroplast transformation vector
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To construct the lettuce chloroplast CTB-FIX expression vector, PCR was first performed to
amplify the CTB-FIX fusion gene with the primer set NdeI-CTB-Fw (5′
TTCATATGACACCTCAAAATATTACTGATT 3′, the underlined nucleotides represent
the start codon of CTB fusion tag) and XbaI-FIX-Rv (5′
GATCTAGATTAAGTGAGCTTTG TTTTTTCCT 3′, the underlined nucleotides indicate
the stop codon of FIX) from a template plasmid pLD CTB-FFIX [11]. The CTB-FIX PCR
products were cloned into pCR-Blunt II-TOPO Vector (Life Technologies Co., Carlsbad,
CA). After verification of nucleotide sequence, the NdeI-CTB-FIX-XbaI fragment was
subcloned into an NdeI-XbaI digested intermediate vector pDVI-1 harboring a lettuce psbA
promoter-5′ UTR and lettuce psbA 3′ UTR. The CTB-FIX expression cassette including the
lettuce psbA promoter-5′ UTR /CTB-FIX /lettuce psbA 3′ UTR was obtained by SalI-NotI
digestion and then cloned into SalI-NotI digested pLS-LF vector [10] to create the CTB-FIX
lettuce chloroplast expression vector pLS-CTB-FIX (Fig. 1A).
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2.2. Transformation and characterization of lettuce transplastomic lines
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Lettuce (Lactuca sativa) cv. Simpson Elite leaves were bombarded with the CTB-FIX
expression vector and the chloroplast transformants were selected on spectinomycin as
previously described [24]. In order to identify the site specific integration of the CTB-FIX
transgene into the chloroplast genome and to verify the homoplasmic plants, PCR analysis
and Southern blot assays were performed according to previous reports from our laboratory
[24,25].
2.3. Lyophilization of the CTB-FIX transplastomic leaves
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Frozen lettuce leaves expressing CTB-FIX fusion proteins were freeze-dried in a lyophilizer
(Genesis 35×L, SP Scientific, Stone Ridge, NY) at −40 °C, −30 °C, −20 °C, −15 °C, −10°C,
−5°C and 25 °C for a total of 72 h under vacuum 400 mTorr. The lyophilized leaves were
ground in a coffee grinder (Hamilton Beach, Southern Pines, NC) at maximum speed for 3
times (each time, pulse on 6 s and off 90 s). The fine powder or lyophilized leaves were
stored in moisture free containers at room temperature with silica gels up to 2 years.
2.4. Analysis of CTB-FIX expression in transplastomic lettuce leaves
Immunoblot analysis and quantitation of the CTB-FIX fusion protein were carried out by
previously reported protocols [5,24]. In order to analyze the pentameric structure of CTBFIX fusion protein expressed in the transformed lettuce chloroplasts, GM1-ganglioside
receptor binding ELISA and non-reducing gel-western blot assays were performed as
reported earlier [5].
2.5. Hemophilia B mouse experiments
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Hemophilia B mice with F9 gene deletion on C3H/HeJ background (C3H/HeJ F9−/−) were
bred as previously published [11,26,27]. Male mice approximately 2 months of age were
used at the onset of experiments and housed under special pathogen-free conditions at the
University of Florida under institutionally approved protocols. Lyophylized plant material
was rehydrated in sterile PBS to a final volume of in 200 μl per gavage dose (containing
1.5–15 μg of CTB-FIX antigen) and briefly homogenized on ice for <30 sec with an OMNI
International (GLH-2596) probe. Oral delivery was performed twice per week for 8 weeks
by gavage using a 20-G bulb-tipped gastric gavage needle. For FIX replacement therapy,
mice were administrated 1 IU hFIX (Benefix, Pfizer, New York, NY) into the tail vein once
per week for 8 weeks. Blood was collected by tail bleed into citrate buffer. To prevent fatal
anaphylaxis in control animals (that did not receive oral tolerance), anti-histamine and antiplatelet activating factor (anti-PAF) were administered starting at the 4th injection [11,13].
Antibody formation against FIX in murine plasma was measured by Bethesda assay (using a
fibrometer from Stago, Pasippany, NJ) and by immunoglobulin-specific ELISA as published
[11,13]. Frozen tissue sections from small intestine were prepared for
immunohistochemistry and stained for FIX and CD11c antigens as previously documented
[13].
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2.6. Scaled-up hydroponic cGMP production of CTB-FIX biomass
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A hydroponic system amenable to development into a cGMP pilot-scale production system
was assembled. The hydroponic system consisted of two wire shelving units. In each rack
there were four growing areas that were illuminated with three sealed lighting fixtures
containing 2-T8 fluorescent bulbs. Two growth trays containing rockwool horticultural
substrate (Grodan, The Netherlands) were placed on each shelf. The nutrient comprised a
20-10-20 ratio of nitrogen, phosphorus and potassium.
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CTB-FIX seeds were placed on the rockwool surface at 2 inch × 2 inch spacing. Plants
received an average of 70 – 90 μmol m−2 s−1 of light on an 18 hour photoperiod. The
temperature and humidity in the growth room ranged from 23–26°C and 20–60%,
respectively. This hydroponic plant growth system is a small-scale arrangement that can be
scaled to cGMP pilot scale production [28]. For a comparison of germination and biomass
accumulation rates, CTB-FIX plants were grown alongside the commercial cultivar Simpson
Elite.

3. Results
3.1. Lettuce CTB-FIX chloroplast expression vector
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Our goal is to create an edible leafy crop plant (lettuce) capable of producing adequate levels
of FIX antigen in chloroplasts to facilitate clinical translational studies. In order to enhance
transformation efficiency, lettuce species specific chloroplast vector was constructed using
endogenous full length (~2 kb /flank) flanking sequences. Likewise, we used lettuce psbA
promoter, 5′UTR and 3′UTR to enhance transgene expression. These concepts formed the
basis for design and construction of pLS-CTB-FIX expression vector (Fig. 1A). For
expression of FIX antigen, an N-termial truncated version (47th – 461st amino acids) of
human FIX cDNA (FR846240.1) excluding the signal peptide (1st – 28th) and propeptide
(29th – 46th) was used to generate the CTB-FIX expression vector. The vector contained the
spectinomycin selection marker gene aadA which could be removed by direct repeats (see
discussion section). In addition, a glycine-proline-glycine-proline (GPGP) hinge to prevent
steric hindrance was created between CTB and FIX fusion elements. A furin cleavage site
(RRKR) was also included in this CTB-FIX expression vector [11]. While this construct
lacks the FIX propeptide (which is required for γ-carboxylation) and thus cannot produce
functional FIX, the entire amino acid sequence of mature FIX is included, covering all
potential CD4+ T cell epitopes for tolerance induction.
3.2. Characterization of CTB-FIX transplastomic lettuce lines
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CTB-FIX transplastomic lettuce lines were created by biolistic particle bombardment of
lettuce leaves from a commercial cultivar (Simpson Elite) with the expression vector pLSCTB-FIX. PCR results showed the correct sizes of amplicons, 2.77 kb with primer set 16SFw/3M, 3.60 kb with 5P/2M and 1.34 kb with CTB-Fw/FIX-Rv1 (Fig. 1A and 1B). The
site-specific integration of the CTB-FIX gene into the chloroplast genome was further
confirmed by Southern blot analysis probed with the lettuce trnI and trnA flanking sequence.
All three independent transplastomic lines showed distinct hybridizing fragments in
Southern blots with the expected size of 12.6 kb but not the 9.1 kb fragment from

Biomaterials. Author manuscript; available in PMC 2016 November 01.

Su et al.

Page 6

Author Manuscript

untransformed wild type plants (Fig. 1A, 1C), confirming that all three CTB-FIX
transplastomic lines were homoplasmic (in which all chloroplast genome have been
transformed with insertion of the transgene cassette).
3.3. Folding, stability and CTB-FIX pentamer assembly in lyophilized lettuce leaves
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Total leaf proteins were extracted with a fully denatured and reducing buffer to analyze
CTB-FIX protein. As shown in Figure 2A, the monomer CTB-FIX fusion protein with the
correct molecular mass of 59.2 kDa was detected with anti-CTB or FIX antibody. All
transplastomic lettuce lines expressing CTB-FIX were fertile and set seeds. In T1 plants,
CTB-FIX expression levels of the young, mature and old leaves were 0.63%, 0.58% and
0.48% of total leaf protein (TLP) respectively (Fig. 2B). The CTB-FIX concentration of the
frozen mature leaves was up to 58.38 μg per g of fresh leaves. CTB-FIX pentamer (296.0
kDa) properly assembled in the transgenic lettuce chloroplasts (Fig. 2C). Absence of any
cleaved products affirms stability of assembled pentamers in plant extracts.
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Frozen CTB-FIX lettuce mature leaves were freeze-dried using a lyophilizer as described in
the methods section. Figure 3A shows a direct comparison of protein concentrations in
lyophilized and frozen leaf samples by weight (5–200 μg, 1–40 X dilution) and an increase
of 18–21 fold CTB-FIX protein concentration was observed after lyophilization. The intact
monomer band of CTB-FIX fusion protein was observed without any detectable degradation
of CTB-FIX in all tested lyophilized samples after storage for 2, 6, 12 and 24 months, at
ambient temperature (Fig. 3B), confirming that CTB-FIX protein is stable in the freeze-dried
lettuce leaves up to 2 years. The stability of the CTB-FIX fusion protein concentrations was
similar in all tested samples when normalized for total protein concentration. CTB-FIX
concentrations were 0.59% TLP (equivalent to1478.54 μg/gDW) after 2 month storage,
0.56% TLP (equivalent to 1155.60 μg/gDW) after 6 month storage, 0.54% TLP (equivalent
to 846.43 μg/gDW) after 12 month storage and 0.57% TLP (equivalent to 927.02 μg/gDW)
after 24 month storage. The results of Paired student’s t-test indicated absence of any
significant difference in % TLP of CTB-FIX among lyophilized samples stored for different
durations at ambient temperature.
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A plasma membrane receptor (GM1-ganglioside) binds CTB in vivo, and pentamer
formation of CTB is required for binding to GM1 receptor [29,30]. To further test if the
pentameric structure with disulfide bonds was maintained in lyophilized lettuce leaves,
GM1-ganglioside receptor binding ELISA was carried out using the lyophilized leaves after
long term storage at ambient temperature. CTB-FIX fusion protein extracts from all tested
samples showed strong binding affinity to GM1 (Fig. 3C), demonstrating the presence and
functional stability of the CTB-FIX pentamers in lyophilized leaves even after long term
storage (~2 years).
3.4. Scale up of biomass and CTB-FIX dose evaluation in capsules
CTB-FIX lettuce plants were transplanted into potted soils in the greenhouse to set seeds.
For production of CTB-FIX in a scalable hydroponic system, CTB-FIX seeds were
germinated on rockwool or in Petri dishes on filter paper with the nutrient solution. The
germination rate of CTB-FIX lettuce seeds on rockwool was 93% when compared to 100%
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in Petri dishes on filter paper with the nutrient solution. After 32 days of growth, the WT
Simpson Elite plants produced more leaf biomass (236.72 g per flat) than CTB-FIX plants
(144.89 g per flat). This difference in biomass accumulation was anticipated based on the
additional burden of constitutively synthesizing a foreign human protein (Fig. 4A). The
CTB-FIX protein concentration in the lyophilized lettuce leaves collected from the
hydroponic system contained 0.38% TLP (equivalent to 1,007.55 μg/gDW) which is lower
than 0.56% TLP (equivalent to 1,459.59 μg/gDW) in lyophilized CTB-FIX lettuce leaves
harvested from the Daniell lab greenhouse at the University of Pennsylvania (Fig. 3D). Two
batches of leaves from different harvests at Fraunhofer (32, 51 days old) and UPenn
greenhouse (66, 86 days old) samples were analyzed. Based on the current yield of FIXlettuce production in the hydroponic system, ~870 kg of fresh FIX-lettuce leaves (~43.5 kg
dry weight) can be harvested per thousand ft2 of growth room annually. Up to 43.5 g of FIX
can be produced from 43.5 kg of dry FIX-lettuce leaves, yielding 24,000–36,000 doses for
20-kg pediatric patients (based on the lowest or highest effective dose for induction of oral
tolerance). After lyophilization, the freeze-dried FIX lettuce leaves were ground into fine
powder and used to prepare FIX-lettuce capsules (Fig. 4B).
3.5. Oral delivery of CTB-FIX lettuce cells suppressed inhibitor formation against FIX in
hemophilia B mice

Author Manuscript

First, we wanted to confirm that oral administration of CTB-FIX bioencapsulated in lettuce
cells results in delivery of the FIX antigen to the gut immune system. Lyophilized lettuce
(after storage for eight months at ambient temperature) plant cells (containing 10 μg CTBFIX) were resuspended in sterile PBS and delivered to hemophilia B mice by oral gavage.
Five hours later, the small intestine was removed. Immunohistochemical staining of
cryosections confirmed delivery of FIX antigen to the gut epithelium and to Peyer’s patches
(Fig. 5A), with efficiency similar to our previous observations on FVIII and FIX delivery of
tobacco cells [11–13]. Uptake of FIX antigen to dendritic cells (DC) was demonstrated by
co-localization with CD11c+ cells (DCs, Fig. 5B–D). Systemic delivery of FIX antigen was
observed 2 and 5 hrs after gavage of lettuce cells at levels similar to those achieved from
feeding of identical antigen doses contained in tobacco cells (Fig. 5E).
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Next, hemophilia B mice received oral gavages of the lettuce material twice per week for 2
months (Fig. 6A). A ten-fold dose escalation (1.5 μg or 15 μg) of CTB-FIX (in 1.9 or 19 mg
lyophilized lettuce cells) was investigated. Control mice received WT untransformed lettuce.
During the second month of this regimen, all mice (n=11 for control and low dose, n=7 for
high dose) were additionally i.v. injected with recombinant FIX (1 IU) once per week. This
replacement therapy was continued for 1 month after oral gavages had been stopped (Fig.
6A). Blood samples were collected 1 week after the last FIX injection. FIX inhibitor titer
was robustly suppressed by oral delivery of CTB-FIX expressing lettuce cells for both doses
(Fig. 6B). Average titers were 15–fold lower, and 10 of 11 mice in the low-dose and 5 of 7
mice in the high-dose group had very low (<2 BU) to undetectable inhibitor titers. In
contrast, control mice formed high-titer inhibitors (11/11 >5BU, with 9/11 >10 BU). IgG1
was the dominant subclass of IgG produced against FIX. Average IgG1 titers were
suppressed by 3–fold, and – in contrast to control mice – no titers >20,000 ng/ml were
measured (Fig. 6C). Because repeated i.v. delivery of FIX causes not only inhibitor
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formation but also fatal anaphylaxis in the C3H/HeJ F9−/− strain, control mice were
additionally treated with drugs that prevent anaphylactic reactions. Mice that had received
oral tolerance using high- or low-dose CTB-FIX in lettuce, despite not being treated with
these drugs, did not develop anaphylaxis, consistent with suppression of IgE formation (Fig.
6D). At the end of these experiments, different organs were analyzed for induction of LAP+
Treg by flow cytometry. A significant increase in the frequency of LAP+CD25−CD4+ Treg
was found in the spleen, mesenteric lymph nodes, and Peyer’s patches (but not in control
lymph node) of FIX fed mice (Fig. 6E).

4. Discussion
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Even though one protein drug made in carrot cells has been approved by FDA [1], this did
not eliminate prohibitively expensive fermentation, purification, cold storage or
transportation costs. Therefore, this reports the first clinical advancement of a protein drug
made in edible plant cells for oral drug delivery. Successful generation of transplastomic
lettuce plants at an industrial scale is a major step towards development of a clinical protocol
for inducing oral tolerance in hemophilia patients.
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In addition, fusion to CTB ensures highly efficient targeting of the gut immune system for
oral tolerance induction [10–13]. CTB assembles into a stable pentameric ring consisting of
five identical 11.5-kDa polypeptide monomers. CTB pentamers bind to GM1 ganglioside
receptors on the membranes of gut epithelial cells and on DCs [10–13, 31, 32]. Role of CTB
in induction of oral tolerance has been reported by several investigators [10–13, 33, 34].
Clinical data to support the safety of CTB administration to humans [35] has already been
approved for human use a decade ago and is used by hundreds of millions of people around
the globe [36]. The successful induction of oral tolerance by CTB-autoantigen conjugates in
experimental systems has been also proven to be safe in clinical trials [37]. Extensive preclinical evaluation leading to these clinical studies have shown that recombinant CTB or
CTB fusions do not cause histopathology in the small intestine, nor do they increase
vascular permeability [38].
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CTB may enhance tolerance induction also by induction of indoleamine 2, 3-dioxygenase
(which is known to aid in Treg induction) in DC [39]. Upon uptake by epithelial cells, FIX
is cleaved off at the engineered Furin cleavage site and in part systemically delivered [11].
Furthermore, FIX antigen is delivered to several subsets of antigen presenting cells (APCs)
in the GALT. These include F4/80+ cells in the duodenum and CD11c+ DC (including
tolerogenic CD103+ DC) in the lamina propria and in Peyer’s patches (PP) throughout the
small intestine [13]. Direct uptake by DC that sample the gut lumen and transport to DC in
PP by M cells likely also contribute to antigen uptake resulting in an increase in several
subsets of DCs and CD4+ T cells. IL-10 dependent and antigen-specific immune regulatory
response ultimately suppresses systemic antibody formation via induction of
CD4+CD25+FoxP3+ Treg and CD4+CD25−FoxP3−LAP+ Treg [13]. LAP+ Treg overexpress
TGF-β (resulting in detectable latency associated peptide (LAP) on the cell surface, suppress
via a TGF-β dependent mechanism, and may be more immune suppressive than FoxP3+
Treg [40,41]. Upon systemic challenge with FVIII or FIX, our oral tolerance protocol
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increases the overall frequency of LAP+ Treg, and these induced Treg up-regulate IL-10 and
TGF-β expression in response to antigen [12, 13].
Use of freeze-dried plant cells facilitates pharmaceutical production and formulation. In this
study, we observed that CTB-FIX fusion protein in lyophilized lettuce can be stored at room
temperature up to 2 years without any detectable degradation of this protein. We used
material that had been stored for 8 months to tolerize the hemophilic mice over a wide dose
range. The long-shelf-life of freeze-dried CTB-FIX lettuce leaves eliminates the need for
expensive protein purification, cold storage, cold transportation and addresses a major
challenge in production and delivery of current protein drugs. Therefore, lettuce-made FIX
would be ideal for large scale and cost effective production of this biopharmaceutical for
translational studies of hemophilia B.
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In the present study, no significant difference for oral tolerance induction was observed
between low-dose-(1.5 μg of CTB-FIX) and high-dose-treated (15 μg of CTB-FIX)
hemophilia B mice, which may be due to highly efficient CTB-mediated delivery of FIX
antigen. This will be a major advantage in further clinical advancement to overcome
potential differences among patients in efficiency of oral delivery of protein drugs
bioencapsulated in plant cells. In the unlikely event of requiring lyophilized materials with
higher dose (which could be simply achieved by taking more capsules), codon optimized
genes could be used instead of native human genes. An additional improvement needed may
be the removal of selectable marker gene from transformed chloroplast genomes. Several
methods are readily available for removal of the selection marker genes [42, 43]. Precise
excision of the selectable marker gene (aadA) was also accomplished recently from the
integration site (trnA/trnI) used in this study with Bxb1 recombinase and attP/attB
recognition sites [44].
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The demonstration of growing CTB-FIX and WT lettuce (cv. Simpson Elite ) plants in a
controlled environment hydroponic system illustrates that transformed plants performed well
using scalable production methods that are translatable to cGMP (current Good
Manufacturing Practices). There was no need to germinate seeds in the presence of
antibiotic. The indoor hydroponic system does not require use of pesticides and herbicides.
This system can also avoid soil borne diseases. The fast growth rate is another unique
advantage of the hydroponic system and one-month-old FIX-lettuce leaves were ready for
the first harvest. This opens a path towards human clinical evaluation of CTB-FIX, as well
as other similarly expressed proteins. For example, existing plant-based biopharmaceutical
production facilities operated under the FDA’s GMP guidelines can potentially be modified
to accommodate lettuce biomass production [28]. Under current growth condition, the CTBFIX concentration in the lettuce leaves harvested from the hydroponic system was not as
high as that from UPenn Daniell lab greenhouse (1mg/g vs 1.5 mg CTB-FIX/g DW). This
difference may be mainly due to different light source and 3-fold lower intensity (sunlight
~280 μmol m−2 s−1 vs hydroponic system ~90 μmol m−2 s−1 ) because of the light-regulated
psbA promoter-5′ UTR determining expression level of CTB-FIX protein.
Mechanistic studies to understand molecular basis of tolerance conferred by different blood
clotting factors expressed in plant cells and efficacy of this system to not only induce
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tolerance but also accomplish reversal [11–13] augurs well for further clinical advances. In
this study for oral tolerance induction, the propeptide sequence of FIX was not included in
the CTB-FIX fusion protein expressed in lettuce chloroplasts. It has been demonstrated that
this propeptide is required for gamma-carboxylation of the Gla domain of the mature protein
to produce functional FIX [45]. Therefore, the lettuce chloroplast-expressed FIX from this
study does not have blood clotting activity. Future studies will explore delivery of functional
clotting factors. Most importantly, elimination of prohibitively expensive fermentation,
purification, cold storage/transportation, short shelf life of current protein drugs makes this
novel approach highly efficient, cost-effective and environmentally friendly for large scale
production of therapeutic proteins in plants, a major milestone in advancing this field.
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Figure 1. CTB-FIX lettuce chloroplast expression vector and evaluation of site-specific
integration the lettuce chloroplast genome

Author Manuscript

(A) Schematic diagram of CTB-FIX lettuce expression vector pLS-CTB-FIX. Homologous
chloroplast genome flanking sequences include 16S (16S rRNA), isoleucine tRNA (trnI),
alanine tRNA (trnA) genes. A glycine-proline-glycine-proline hinge and furin cleavage site
(RRKR) are inserted between CTB and the FIX sequence. The CTB-FIX expression is
regulated by the lettuce psbA promoter-5′ UTR (PpsbA) and 3′ UTR (TpsbA). The selection
marker gene aadA (encoding aminoglycoside 3′-adenylyltransferase gene to confer
spectinomycin resistance) is driven by a ribosomal RNA operon promoter (Prrn) with
GGAG ribosome binding site. (B) PCR analysis of the CTB-FIX transplastomic lines. The
primer annealing sites (16S-Fw/3M, 5P/2M and CTB-Fw/FIX-Rv1) for PCR analysis of
control and transplastomic lines are shown in Figure 1a. L1, L2 and L3 represent three
independent transplastomic lines. (C) Evaluation of homoplasmy in CTB-FIXtransplastomic lines. Total lettuce DNA was digested with HindIII and probed with 32Plabeled 1.12 kb trnI/trnA flanking region fragment. Untransformed line generates a 9.1 kb
hybridizing fragment while transplastomic lines generate 12.6 kb fragment due to site
specific integration of the transgene cassette.
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Figure 2. Evaluation of CTB-FIX expression in the lettuce transplastomic lines
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(A) Western blot analysis of CTB-FIX in three independent lines and WT controls. Plant
total leaf proteins (5 μg/lane) were loaded from WT and CTB-FIX plants. CTB, 3 ng per
lane. L1, L2, L3: 3 independent lettuce transplastomic lines. WT, untransformed wild type
plant. Antibody titers: rabbit anti-CTB polyclonal antibody 1:10,000; goat anti-FIX
polyclonal antibody 1:2,000. (B) Quantitation of CTB-FIX expression at different
developmental stages. Total leaf protein (1.5 μg per lane) was loaded from young, mature
and old leaves (2.5-months-old plants grown in the greenhouse). Probe: anti-CTB rabbit
polyclonal antibody (titer 1:10,000). Right bar graph shows CTB-FIX concentrations of
young, mature and old leaves. Data shown are means ± SD of two replicates from leaves
collected from two independent lines. (C) Non-reducing gel western blot analysis. Probe,
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anti-CTB rabbit polyclonal antibody (titer 1:10,000). Protein concentration loaded: CTB, 3
ng per lane; CTB-FIX (L1, L2 and L3) and WT leaf extracts, 5 μg (TLP) per lane.
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Figure 3. Evaluation of CTB-FIX concentration and stability after long term storage of
lyophilized lettuce leaves
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(A) Comparison of CTB-FIX protein concentration of lyophilized CTB-FIX lettuce leaves
with the frozen leaf samples. 1× 40× indicate fold of dilution. One fold (1×) equals 200 μg
(in3 weight) of leaf ground powder. (B) Evaluation of CTB-FIX protein stability in
lyophilized lettuce leaves during long term storage at ambient temperature. Two
independent blots by loading either 2.0 μg or 1.5 μg of TLP per lane are shown. Probe: antiCTB rabbit polyclonal antibody (titer, 1:10,000). Right bar graph shows the CTB-FIX
concentrations of the 4 batches of lyophilized leaves after different periods of storage (2, 6,
12 and 24 months). Data shown are means ± SD of three independent experiments. (C) GM1
binding assay. CTB: CTB standard protein (5 ng). Lyo-2M, Lyo-6M, Lyo-12M, Lyo-24M:
Total soluble protein (TSP, 100 μg) from the lyophilized CTB-FIX expressing leaves after
storage for 2, 6, 12 and 24 months at room temperature. Lyo-WT, protein extract (100 μg,
TSP) from lyophilized and untransformed wild type leaves. BSA, bovine serum albumin
(100 μg). Data shown are means ± SD of two independent experiments. (D) Comparative
analysis of CTB-FIX protein concentrations in lyophilized lettuce leaves from Fraunhofer
(Fraun, hydroponic system) with leaf samples collected from the Daniell lab greenhouse at
University of Pennsylvania (UPenn, potted soils). 1.5 μg TLP per lane was loaded. Probe:
anti-CTB rabbit polyclonal antibody (titer, 1:10,000). Left panel represents results of the 1st
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leaf harvest (plant ages: Fraunhofer, 32-days-old; UPenn, 66-days-old) and the right panel
shows results of the 2nd leaf harvest (plant ages: Fraunhofer, 51-days-old; UPenn, 86-daysold).
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Figure 4. Industrial production of FIX bioencapsulated in lettuce cells
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(A) Biomass production of CTB-FIX lettuce. CTB-FIX lettuce plants were grown in potted
soils in the Daniell lab greenhouse at the University of Pennsylvania or in Fraunhofer cGMP
hydroponic system (Upper 2 panels). The lower 2 panels show the growth status of CTBFIX lettuce (cv. Simpson Elite, 24 days old) and wild type (WT) lettuce (cv. Simpson Elite,
24 days old). (B) Capsule preparation. A large scale production of FIX-expressing lettuce
was established in Fraunhofer USA (Newark, DE). After harvesting and lyophilization
(Lyophilizer: Genesis 35×L, SP Scientific, Stone Ridge, NY) of the fresh leaves, the freezedried FIX leaves were powdered and prepared as capsules.
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Figure 5. FIX antigen delivery to the small intestine of hemophilia B mice
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(A) FIX (red) delivered to epithelium of intestinal villi and to Peyer’s patches (PP). DAPI
was used to stain nuclei blue. (B) Examples of co-localization (arrows) of FIX antigen and
CD11c+ cells, indicating antigen delivery to DC in PP. (C) Examples of co-localization
(arrows) of FIX antigen and CD11c+ cells, indicating antigen delivery to DC in villi. Mice
had received oral gavages of CTB-FIX expressing lettuce (but no i.v. FIX). (D) No FIX stain
was observed in mice that received oral gavage of WT lettuce (shown), or in intestinal
sections of CTB-FIX fed mice when the primary antibody against FIX was omitted during
staining (not shown). Original magnification for all panels: 200×. (E) Systemic human FIX
levels as measured by ELISA 2 and 5 hrs after oral gavage of 10 μg CTB-FIX
bioencapsulated in lettuce or tobacco cells. Data shown are average ± SD (n=3/group).
Differences between lettuce and tobacco were not significant (“ns”).
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Figure 6. Suppression of inhibitor and IgE formation against FIX in hemophilia B mice
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(A) Mice were given two gavages weekly (of different CTB-FIX doses) of lettuce cells and
were challenged with i.v. injections of FIX. (B) Anti-FIX titers 1 week after the last i.v.
injection of FIX are graphed as inhibitor titers in BU/ml. (C) IgG1, 2a, and 2b anti-FIX
titers. (D) IgE anti-FIX titers. (E) Frequencies of LAP+CD25−CD4+ Treg in the spleen,
mesenteric lymph nodes, Peyer’s patches, and control (inguinal) lymph nodes of FIX fed
and control mice. Flow plots on the left show individual representative examples. Graph to
the right shows results for individual mice (n=5/group) as well as averages ± SD.

Author Manuscript
Biomaterials. Author manuscript; available in PMC 2016 November 01.

